Clinical Trials

Imetelstat, a first-in-class telomerase inhibitor and our sole product candidate, is being developed for the potential treatment of hematologic myeloid malignancies. Imetelstat is currently in two clinical trials being conducted by Janssen under the terms of an exclusive  worldwide collaboration and license agreement.

Imetelstat

IMbark Trial

Myelofibrosis

Clinical trial in intermediate-2 or high-risk MF patients who are relapsed after or refractory to JAK inhibitor treatment.
 

Partner
janssen logo

Phase 2

Imetelstat

IMerge Trial

Myelodysplastic Syndromes

Clinical trial in transfusion dependent patients with low or intermediate-1 risk MDS who are relapsed after or refractory to treatment with an erythropoiesis stimulating agent (ESA).

Partner
janssen logo

Phase 2/3

 

For background information on clinical trials: